MentionFox
Home › Executive changes › Monte Rosa Therapeutics, Inc.
Leadership changes · GLUE · SEC Form 8-K, Item 5.02

Leadership changes at Monte Rosa Therapeutics, Inc. (2026)

Before you join, sell to or invest in Monte Rosa Therapeutics, Inc.

MentionFox check on Monte Rosa Therapeutics, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/monte-rosa-therapeutics

Check Monte Rosa Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Monte Rosa Therapeutics, Inc.?

Who joined and who left Monte Rosa Therapeutics, Inc. (GLUE)? 1 departure reported on 2026-02-10, each cited to the company's own filing.

Edmund Dunn's departure as Controller of Monte Rosa Therapeutics, Inc. was reported, effective April 3, 2026; the filing names no successor. As of November 14, 2026, Monte Rosa Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 10, 2026, naming 1 departure (Form 8-K, February 10, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies ↓

Sell to companies like Monte Rosa Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Out (departing)1
Latest filing2026-02-10

Monte Rosa Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-10. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Monte Rosa Therapeutics, Inc. files it.

Also on the record for Monte Rosa Therapeutics, Inc.

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G, by Vestal Point Capital, LP5.4% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Montanova Capital, LLC4.2% of the class5%+ stakesSource
July 8, 2026Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc.10.5% of the class5%+ stakesSource
July 6, 2026Stake report, Schedule 13D/A, by New Enterprise Associates 17, L.P.7.9% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Baker Bros. Advisors LP9.99% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL6.3% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Chen Yu5.5% of the class5%+ stakesSource
April 22, 2026Stake report, Schedule 13G/A, by Adam Goulburn8.1% of the class5%+ stakesSource
March 19, 2026Stake report, Schedule 13D/A, by New Enterprise Associates 17, L.P.9.7% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Baker Bros. Advisors LP6.7% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL5.9% of the class5%+ stakesSource
January 21, 2026Stake report, Schedule 13G/A, by Adam Goulburn8.7% of the class5%+ stakesSource

Selling to them or working with them? See who runs Monte Rosa Therapeutics, Inc. now and the warning signs.

Watch Monte Rosa Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Monte Rosa Therapeutics, Inc. and the records around it.

Monte Rosa Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Monte Rosa Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Monte Rosa Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Monte Rosa Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 20 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-10OutController2026-04-038-K, 2026-02-10

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Monte Rosa Therapeutics, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Monte Rosa Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Monte Rosa Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Monte Rosa Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Controller at Monte Rosa Therapeutics, Inc., with the record behind each one.

Find candidates like Controller at Monte Rosa Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-02-10 · 8-K

Departing: Edmund Dunn, Controller, effective 2026-04-03

On January 9, 2026, Edmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc. (the " Company "), effective as of April 3, 2026.

Also stated in this filing

  • Mr. Dunn will not receive any severance payments or benefits in connection with his departure.
  • Effective April 3, 2026, Matthew Bowen, currently an employee of the Company, will succeed Mr. Dunn as Corporate Controller and Principal Accounting Officer of the Company.
  • Mr. Bowen, age 37, joined the Company's finance department following the Company's initial public offering in June 2021 to support the enhanced financial reporting and compliance requirements associated with operating as a public company.
  • Since joining the Company, Mr. Bowen has served in roles of increasing responsibility over the past nearly five years, most recently as Director, Finance.
  • Prior to joining the Company, Mr. Bowen spent seven years in the audit and assurance practice at Ernst & Young LLP, where he primarily worked on audits of large public companies.
  • Mr. Bowen holds a Bachelor of Science and a Master's in Accounting from Bryant University and is a licensed Certified Public Accountant in the Commonwealth of Massachusetts.

Tools for this story

Each opens in a new tab, filled in for Monte Rosa Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/monte-rosa-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Monte Rosa Therapeutics, Inc. executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/monte-rosa-therapeutics